Intravenous Stable Isotope Glycerol for Clinical Research
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has issued a Presolicitation for the procurement of Intravenous Stable Isotope Glycerol for clinical research. This opportunity is designated as an 8(a) Set-Aside. The contractor will be responsible for sourcing, manufacturing, and releasing the isotope product to the NIH Clinical Center Pharmacy. Responses are due June 11, 2026.
Scope of Work
The selected contractor will provide intravenous stable isotope glycerol, which is crucial for human metabolic clinical studies. Key responsibilities include:
- Sourcing the raw material.
- Packaging and/or manufacturing the isotope product.
- Submitting and releasing the product to the NIH Clinical Center Pharmacy.
- Ensuring the product meets microbial and analytical testing requirements.
This procurement is initiated on behalf of NIDDK principal investigators and must adhere to the minimum requirements outlined by the NIH Sterile Products for Human Administration (SPHA) Executive Committee and the NIH Office of Research Support and Compliance.
Contract & Timeline
- Type: Presolicitation
- Set-Aside: 8(a) Set-Aside (FAR 19.8)
- Product Service Code: 6810 (Chemicals)
- Response Date: June 11, 2026, 1:00 PM ET
- Published Date: June 11, 2026, 10:39 AM ET
- Place of Performance: Bethesda, MD 20892, United States
Evaluation
As a presolicitation, specific evaluation criteria are not yet detailed but will likely focus on the contractor's ability to meet the stringent requirements for stable isotopes used in human clinical research, including sourcing, manufacturing, and quality control.
Additional Notes
This requirement supports NIDDK's mission to conduct and support medical research into diabetes, digestive diseases, and other metabolic conditions to improve public health. Stable isotopes are vital for generating knowledge in human metabolism that may not be possible through other methods.